Regeneron Pharmaceuticals Inc (NASDAQ:REGN) had an increase of 9.96% in short interest. REGN’s SI was 3.00M shares in June as released by FINRA. Its up 9.96% from 2.72 million shares previously. With 849,400 avg volume, 4 days are for Regeneron Pharmaceuticals Inc (NASDAQ:REGN)’s short sellers to cover REGN’s short positions. The SI to Regeneron Pharmaceuticals Inc’s float is 3.81%. The stock decreased 0.12% or $0.37 during the last trading session, reaching $315.3. About 751,767 shares traded. Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) has declined 35.54% since June 16, 2017 and is downtrending. It has underperformed by 48.11% the S&P500. Some Historical REGN News: ; 01/05/2018 – DEAL WITH REGENERON, SANOFI COMES AFTER DRUGMAKERS CUT PRICE; 10/03/2018 – Regeneron and Sanofi Plan to Cut Cholesterol Drug Price in Exchange for Wider Coverage; 16/05/2018 – REGENERON, SANOFI: POSITIVE DATA FOR CEMIPLIMAB; 19/03/2018 – EYLEA® (AFLIBERCEPT) INJECTION SHOWS POSITIVE TOPLINE RESULTS; 23/04/2018 – Regeneron Announces Upcoming Investor Conference Presentations; 11/05/2018 – BAYER AG BAYGn.DE – BAYER RECEIVES APPROVAL FOR EYLEA® IN CHINA; 03/04/2018 – REGENERON PHARMACEUTICALS INC REGN.O – EUROPEAN MEDICINES AGENCY (EMA) HAS ACCEPTED FOR REVIEW AN APPLICATION FOR DUPIXENT; 30/04/2018 – Sanofi, Regeneron: FDA to Conduct Priority Review of Cemiplimab as a Potential Treatment for Advanced Cutaneous Squamous Cell Carcinoma; 21/05/2018 – Sanofi SA: New England Journal of Medicine Publishes Two Positive Phase 3 Trials Showing Dupixent Improved Moderate-To-Severe Asthma; 21/03/2018 – ALNYLAM PHARMACEUTICALS INC – REGENERON WILL CONTRIBUTE RESEARCH ON HEPATOCYTE-EXPRESSED, GENETICALLY-VALIDATED HSD17B13 TARGET
Bahl & Gaynor Inc increased Nic Inc (EGOV) stake by 15.22% reported in 2018Q1 SEC filing. Bahl & Gaynor Inc acquired 72,880 shares as Nic Inc (EGOV)’s stock rose 8.54%. The Bahl & Gaynor Inc holds 551,740 shares with $7.34 million value, up from 478,860 last quarter. Nic Inc now has $1.08 billion valuation. The stock increased 1.88% or $0.3 during the last trading session, reaching $16.25. About 447,805 shares traded. NIC Inc. (NASDAQ:EGOV) has declined 26.51% since June 16, 2017 and is downtrending. It has underperformed by 39.08% the S&P500. Some Historical EGOV News: ; 18/04/2018 – Colorado Department of Public Safety’s Division of Criminal Justice Website Honored with Award; 30/04/2018 – NIC 1Q Rev $86.7M; 28/03/2018 – West Virginia Human Rights Commission Launches New Mobile-Friendly Website; 20/03/2018 – NIC Non-Deal Roadshow Scheduled By Maxim Group LLC for Mar. 27; 09/04/2018 – NIC to Host Annual Stockholder Meeting on May 1; 22/03/2018 – NIC GROUP PLC – BOARD HAS RESOLVED TO RECOMMEND TO THE SHAREHOLDERS PAYMENT OF A FIRST AND FINAL DIVIDEND FOR THE YEAR OF SHS 1.00 PER ORDINARY SHARE; 24/04/2018 – Colorado Department of Regulatory Agencies’ Website for Military & Veterans Programs Receives Award for Streamlining Occupational Licensing; 30/04/2018 – NIC 1Q EPS 23c; 26/04/2018 – Federal Motor Carrier Safety Administration’s Pre-Employment Screening Program Named a Finalist for the ACT-IAC Igniting; 26/04/2018 – NlC’s Gov2Go Platform Named a Finalist for the ACT-IAC lgniting Innovation Awards
Investors sentiment decreased to 1.05 in Q1 2018. Its down 0.12, from 1.17 in 2017Q4. It is negative, as 70 investors sold Regeneron Pharmaceuticals, Inc. shares while 158 reduced holdings. 71 funds opened positions while 169 raised stakes. 69.33 million shares or 0.23% more from 69.17 million shares in 2017Q4 were reported. American Gp invested in 34,785 shares. Endurant Capital Management Limited Partnership has 0.28% invested in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN). Comerica Securities Inc holds 0.04% or 951 shares in its portfolio. Norinchukin Natl Bank The invested 0.04% of its portfolio in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN). Icon Advisers Incorporated invested 0.08% in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN). Inv Management Group Inc Ltd stated it has 0.39% of its portfolio in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN). First Limited Partnership accumulated 148,109 shares or 0.12% of the stock. Zevenbergen Cap Investments owns 124,047 shares for 1.64% of their portfolio. Nuveen Asset Mngmt Ltd Liability Com accumulated 19,761 shares. Stifel Finance Corporation owns 0.05% invested in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) for 47,094 shares. Proshare Advisors Limited Liability Com holds 0.26% or 116,960 shares in its portfolio. Solaris Asset Llc holds 348 shares or 0.79% of its portfolio. Ima Wealth owns 7,003 shares. Prudential Finance holds 0.05% or 85,938 shares. 219,685 are owned by Guggenheim Cap Limited Liability Company.
Since February 9, 2018, it had 0 insider purchases, and 6 sales for $48.41 million activity. GOLDSTEIN JOSEPH L sold $325,600 worth of stock or 1,000 shares. 121,601 shares were sold by Sanofi, worth $37.61 million on Friday, June 8. Another trade for 11,407 shares valued at $3.37 million was sold by STAHL NEIL. The insider SING GEORGE L sold 20,000 shares worth $5.72M.
Regeneron Pharmaceuticals, Inc., a biopharmaceutical company, discovers, invents, develops, makes, and commercializes medicines for the treatment of serious medical conditions worldwide. The company has market cap of $33.98 billion. The Company’s products include EYLEA injection for the treatment of neovascular age-related macular degeneration, diabetic macular edema, and macular edema following retinal vein occlusion; Praluent injection, an adjunct to diet and tolerated statin therapy for the treatment of adults with heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease; and ARCALYST injection for the treatment of cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome in adults and childrenÂ’s. It has a 30.49 P/E ratio. It also markets Kevzara injection for the treatment of rheumatoid arthritis in adults; and ZALTRAP, an injection for intravenous infusion, which is used in combination with 5-fluorouracil, leucovorin, and irinotecan for the treatment of metastatic colorectal cancer.
Among 33 analysts covering Regeneron Pharmaceuticals Inc. (NASDAQ:REGN), 11 have Buy rating, 1 Sell and 21 Hold. Therefore 33% are positive. Regeneron Pharmaceuticals Inc. had 127 analyst reports since July 28, 2015 according to SRatingsIntel. Guggenheim maintained Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) on Thursday, February 8 with “Buy” rating. J.P. Morgan maintained the stock with “Hold” rating in Thursday, August 3 report. The firm earned “Buy” rating on Thursday, September 21 by UBS. On Monday, September 11 the stock rating was maintained by BMO Capital Markets with “Hold”. Canaccord Genuity maintained it with “Buy” rating and $700 target in Wednesday, August 5 report. Robert W. Baird downgraded the stock to “Underperform” rating in Tuesday, August 1 report. J.P. Morgan maintained the stock with “Hold” rating in Monday, August 14 report. The firm earned “Outperform” rating on Thursday, November 5 by RBC Capital Markets. BMO Capital Markets maintained Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) on Tuesday, July 18 with “Hold” rating. The stock has “Hold” rating by Jefferies on Monday, June 5.
More notable recent Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) news were published by: Seekingalpha.com which released: “Zoetis teams up with Regeneron to discover new vet treatments” on June 06, 2018, also Fool.com with their article: “Should CRISPR Stock Investors Worry About Cancer?” published on June 13, 2018, Seekingalpha.com published: “Kiniksa Pharmaceuticals IPO: Cash King” on May 24, 2018. More interesting news about Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) were released by: Streetinsider.com and their article: “Sanofi (SNY), Regeneron (REGN) Announce NEJM Published Pivotal Cemiplimab Trials showing Positive Results in …” published on June 04, 2018 as well as Prnewswire.com‘s news article titled: “Regeneron’s Investigational Ebola Treatment Shipping to Democratic Republic of the Congo for Use in Current Outbreak” with publication date: May 31, 2018.
More recent NIC Inc. (NASDAQ:EGOV) news were published by: Businesswire.com which released: “NIC Inc. and Grand Canyon National Park Partner to Offer Electronic Entrance Passes” on June 14, 2018. Also Businesswire.com published the news titled: “NIC Inc. Receives Prestigious Beacon Award from Outdoor Recreation Roundtable” on June 05, 2018. Bizjournals.com‘s news article titled: “NIC founder leaves the company’s board; two big-time CIOs join on” with publication date: June 11, 2018 was also an interesting one.
Among 9 analysts covering NIC (NASDAQ:EGOV), 1 have Buy rating, 1 Sell and 7 Hold. Therefore 11% are positive. NIC had 19 analyst reports since August 11, 2015 according to SRatingsIntel. The rating was maintained by Imperial Capital on Wednesday, November 18 with “In-Line”. The firm has “Neutral” rating given on Monday, December 19 by Sidoti. The rating was maintained by Stephens with “Hold” on Thursday, February 1. The firm earned “Hold” rating on Friday, August 5 by Maxim Group. The stock has “In-Line” rating by Imperial Capital on Friday, November 18. The firm earned “Outperform” rating on Tuesday, August 11 by Imperial Capital. On Friday, February 5 the stock rating was downgraded by Avondale to “Market Perform”. The firm has “Buy” rating given on Monday, July 17 by Imperial Capital. The rating was downgraded by Sidoti to “Hold” on Friday, July 21. The company was downgraded on Thursday, February 2 by Avondale.
Bahl & Gaynor Inc decreased General Electric Co (NYSE:GE) stake by 163,191 shares to 227,634 valued at $3.07M in 2018Q1. It also reduced Nike Inc Cl B (NYSE:NKE) stake by 8,790 shares and now owns 538,918 shares. 3M Company (NYSE:MMM) was reduced too.